Direct Comparison of HPV16 Serological Assays Used to Define HPV-Naïve Women in HPV Vaccine TrialsSAFAEIAN, Mahboobeh; GHOSH, Arpita; ESSER, Mark et al.Cancer epidemiology, biomarkers & prevention. 2012, Vol 21, Num 9, pp 1547-1554, issn 1055-9965, 8 p.Article

Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese womenSMITH, Jennifer S; LEWKOWITZ, Adam K; PRETORIUS, Robert G et al.International journal of cancer (Print). 2012, Vol 131, Num 6, pp 1388-1395, issn 0020-7136, 8 p.Article

Bill Anthony's influence on apprentices : A panel discussionMINTER, Bill; ESSER, Mark; YERKES, Lawrence et al.Collection management. 2006, Vol 31, Num 1-2, pp 127-138, issn 0146-2679, 12 p.Conference Paper

A novel chemistry for conjugating pneumococcal polysaccharides to luminex microspheresSCHLOTTMANN, Sonela A; JAIN, Neil; CHIRMULE, Narendra et al.Journal of immunological methods. 2006, Vol 309, Num 1-2, pp 75-85, issn 0022-1759, 11 p.Article

Memory T cells and vaccinesESSER, Mark T; MARCHESE, Rocio D; KIERSTEAD, Lisa S et al.Vaccine. 2003, Vol 21, Num 5-6, pp 419-430, issn 0264-410X, 12 p.Article

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents : A randomized controlled trialREISINGER, Keith S; BLOCK, San L; ALVAREZ, Frances B et al.The Pediatric infectious disease journal. 2007, Vol 26, Num 3, pp 201-209, issn 0891-3668, 9 p.Article

Impact of baseline covariates on the immunogenidty of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccineGIULIANO, Anna R; LAZCANO-PONCE, Eduardo; VUOCOLO, Scott C et al.The Journal of infectious diseases. 2007, Vol 196, Num 8, pp 1153-1162, issn 0022-1899, 10 p.Article

Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women : study design and cohort characteristicsSKJELDESTAD, Finn Egil; MEHTA, Vinay; ESSER, Mark T et al.Acta obstetricia et gynecologica Scandinavica. 2008, Vol 87, Num 1, pp 81-88, issn 0001-6349, 8 p.Article

Translational sciences approach to RSV vaccine developmentKURZWEIL, Vanessa; TANG, Roderick; ESSER, Mark T et al.Expert review of vaccines. 2013, Vol 12, Num 9, pp 1047-1060, issn 1476-0584, 14 p.Article

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American womenPEREZ, Gonzalo; LAZCANO-PONCE, Eduardo; VUOCOLO, Scott et al.International journal of cancer. 2008, Vol 122, Num 6, pp 1311-1318, issn 0020-7136, 8 p.Article

Population Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in Men, Women, and Children in AustraliaNEWALL, Anthony T; BROTHERTON, Julia M. L; MACLNTYRE, C. Raina et al.Clinical infectious diseases. 2008, Vol 46, Num 11, pp 1647-1655, issn 1058-4838, 9 p.Article

Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years OldLEVIN, Myron J; MOSCICKI, Anna-Barbara; RADLEY, David R et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 55, Num 2, pp 197-204, issn 1525-4135, 8 p.Article

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialMUNOZ, Nubia; MANALASTAS, Ricardo; BAUTISTA, Oliver et al.Lancet (British edition). 2009, Vol 373, Num 9679, pp 1949-1957, issn 0140-6736, 9 p.Article

Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assayOPALKA, David; PESSI, Antonello; BRAMHILL, David et al.Journal of immunological methods. 2004, Vol 287, Num 1-2, pp 49-65, issn 0022-1759, 17 p.Article

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseasesGARLAND, Suzanne M; HERNANDEZ-AVILA, Mauricio; TADDEO, Frank J et al.The New England journal of medicine. 2007, Vol 356, Num 19, pp 1928-1943, issn 0028-4793, 16 p.Article

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 l1 virus-like particle (VLP) vaccineOLSSON, Sven-Eric; VILLA, Luisa L; ANDERSSON-ELLSTROM, Agneta et al.Vaccine. 2007, Vol 25, Num 26, pp 4931-4939, issn 0264-410X, 9 p.Article

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6,11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions : a combined analysis of three randomised clinical trialsJOURA, Elmar A; LEODOLTER, Sepp; STEBEN, Marc et al.Lancet (British edition). 2007, Vol 369, Num 9574, pp 1693-1702, issn 0140-6736, 10 p.Article

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18VILLA, Luisa L; AULT, Kevin A; KURMAN, Robert J et al.Vaccine. 2006, Vol 24, Num 27-28, pp 5571-5583, issn 0264-410X, 13 p.Article